THE PALLIATIVE ROLE OF HEPATIC ARTERIAL INFUSION AND ARTERIAL OCCLUSION IN COLORECTAL CARCINOMA METASTATIC TO THE LIVER

Y. Z. Patt, S. Wallace, E. J. Freireich, V. P. Chuang, Evan M Hersh, G. M. Mavligit

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Fifty-five patients with metastatic colorectal carcinoma confined to the liver were treated with hepatic arterial infusion of floxuridine and mitomycin C. Tumour response rate was 43·4% and median overall survival was 11 months. Prolonged survival was associated with intentional or inadvertent occlusion of the hepatic artery. The median survival of twenty-four patients with arterial occlusion (15 months) was significantly higher than that of thirty-one patients without arterial occlusion (8 months).

Original languageEnglish (US)
Pages (from-to)349-351
Number of pages3
JournalThe Lancet
Volume317
Issue number8216
DOIs
StatePublished - Feb 14 1981
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Survival
Liver
Floxuridine
Hepatic Artery
Mitomycin
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

THE PALLIATIVE ROLE OF HEPATIC ARTERIAL INFUSION AND ARTERIAL OCCLUSION IN COLORECTAL CARCINOMA METASTATIC TO THE LIVER. / Patt, Y. Z.; Wallace, S.; Freireich, E. J.; Chuang, V. P.; Hersh, Evan M; Mavligit, G. M.

In: The Lancet, Vol. 317, No. 8216, 14.02.1981, p. 349-351.

Research output: Contribution to journalArticle

Patt, Y. Z. ; Wallace, S. ; Freireich, E. J. ; Chuang, V. P. ; Hersh, Evan M ; Mavligit, G. M. / THE PALLIATIVE ROLE OF HEPATIC ARTERIAL INFUSION AND ARTERIAL OCCLUSION IN COLORECTAL CARCINOMA METASTATIC TO THE LIVER. In: The Lancet. 1981 ; Vol. 317, No. 8216. pp. 349-351.
@article{f0b60bcb1ccc4f6ea662ec58b0816b6d,
title = "THE PALLIATIVE ROLE OF HEPATIC ARTERIAL INFUSION AND ARTERIAL OCCLUSION IN COLORECTAL CARCINOMA METASTATIC TO THE LIVER",
abstract = "Fifty-five patients with metastatic colorectal carcinoma confined to the liver were treated with hepatic arterial infusion of floxuridine and mitomycin C. Tumour response rate was 43·4{\%} and median overall survival was 11 months. Prolonged survival was associated with intentional or inadvertent occlusion of the hepatic artery. The median survival of twenty-four patients with arterial occlusion (15 months) was significantly higher than that of thirty-one patients without arterial occlusion (8 months).",
author = "Patt, {Y. Z.} and S. Wallace and Freireich, {E. J.} and Chuang, {V. P.} and Hersh, {Evan M} and Mavligit, {G. M.}",
year = "1981",
month = "2",
day = "14",
doi = "10.1016/S0140-6736(81)91671-8",
language = "English (US)",
volume = "317",
pages = "349--351",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8216",

}

TY - JOUR

T1 - THE PALLIATIVE ROLE OF HEPATIC ARTERIAL INFUSION AND ARTERIAL OCCLUSION IN COLORECTAL CARCINOMA METASTATIC TO THE LIVER

AU - Patt, Y. Z.

AU - Wallace, S.

AU - Freireich, E. J.

AU - Chuang, V. P.

AU - Hersh, Evan M

AU - Mavligit, G. M.

PY - 1981/2/14

Y1 - 1981/2/14

N2 - Fifty-five patients with metastatic colorectal carcinoma confined to the liver were treated with hepatic arterial infusion of floxuridine and mitomycin C. Tumour response rate was 43·4% and median overall survival was 11 months. Prolonged survival was associated with intentional or inadvertent occlusion of the hepatic artery. The median survival of twenty-four patients with arterial occlusion (15 months) was significantly higher than that of thirty-one patients without arterial occlusion (8 months).

AB - Fifty-five patients with metastatic colorectal carcinoma confined to the liver were treated with hepatic arterial infusion of floxuridine and mitomycin C. Tumour response rate was 43·4% and median overall survival was 11 months. Prolonged survival was associated with intentional or inadvertent occlusion of the hepatic artery. The median survival of twenty-four patients with arterial occlusion (15 months) was significantly higher than that of thirty-one patients without arterial occlusion (8 months).

UR - http://www.scopus.com/inward/record.url?scp=0019350450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019350450&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(81)91671-8

DO - 10.1016/S0140-6736(81)91671-8

M3 - Article

C2 - 6162066

AN - SCOPUS:0019350450

VL - 317

SP - 349

EP - 351

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8216

ER -